SI1747001T1 - Upravljanje vmesnih krvavitev v podaljšanih režimih hormonske kontracepcije - Google Patents

Upravljanje vmesnih krvavitev v podaljšanih režimih hormonske kontracepcije

Info

Publication number
SI1747001T1
SI1747001T1 SI200532240T SI200532240T SI1747001T1 SI 1747001 T1 SI1747001 T1 SI 1747001T1 SI 200532240 T SI200532240 T SI 200532240T SI 200532240 T SI200532240 T SI 200532240T SI 1747001 T1 SI1747001 T1 SI 1747001T1
Authority
SI
Slovenia
Prior art keywords
management
breakthrough bleeding
hormonal contraceptive
contraceptive regimens
extended
Prior art date
Application number
SI200532240T
Other languages
English (en)
Inventor
Andreas Sachse
Patricia J. Sulak
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1747001(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of SI1747001T1 publication Critical patent/SI1747001T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
SI200532240T 2004-04-30 2005-04-29 Upravljanje vmesnih krvavitev v podaljšanih režimih hormonske kontracepcije SI1747001T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10
EP05740127.5A EP1747001B1 (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens
PCT/EP2005/004777 WO2005105103A2 (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Publications (1)

Publication Number Publication Date
SI1747001T1 true SI1747001T1 (sl) 2019-02-28

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200532240T SI1747001T1 (sl) 2004-04-30 2005-04-29 Upravljanje vmesnih krvavitev v podaljšanih režimih hormonske kontracepcije

Country Status (29)

Country Link
US (3) US8163721B2 (sl)
EP (1) EP1747001B1 (sl)
JP (4) JP2007535519A (sl)
KR (4) KR20160150113A (sl)
CN (1) CN103127156A (sl)
AR (1) AR048722A1 (sl)
AU (1) AU2005237255B2 (sl)
BR (1) BRPI0510493A (sl)
CA (1) CA2562296A1 (sl)
CR (1) CR8709A (sl)
DK (1) DK1747001T3 (sl)
EA (2) EA031227B1 (sl)
EC (1) ECSP066999A (sl)
ES (1) ES2704999T3 (sl)
HU (1) HUE041475T2 (sl)
IL (1) IL178458A (sl)
LT (1) LT1747001T (sl)
MX (1) MXPA06012567A (sl)
MY (1) MY151322A (sl)
NO (1) NO341685B1 (sl)
NZ (1) NZ586107A (sl)
PA (1) PA8631801A1 (sl)
PE (1) PE20060467A1 (sl)
SG (2) SG152288A1 (sl)
SI (1) SI1747001T1 (sl)
SV (1) SV2006002100A (sl)
TW (1) TWI374735B (sl)
UY (1) UY28875A1 (sl)
WO (1) WO2005105103A2 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
KR20110045065A (ko) * 2008-09-16 2011-05-03 플레이텍스 프로덕츠, 엘엘씨. 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198920B2 (en) 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
UA123099C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована в порожнині рота одиниця дозування, яка містить естетрольний компонент
KR102217942B1 (ko) * 2015-06-23 2021-02-19 라보라토리오스 레온 파르마 에스에이 과한 체중으로 영향 받은 여성 환자를 위한 드로스피레논-기반의 피임제
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN110312512B (zh) 2016-09-30 2023-05-09 梦欧文科学有限责任公司 用于治疗子宫肌瘤和子宫内膜异位症的方法
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) * 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
WO1993013801A1 (en) 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
PT956024E (pt) * 1996-07-26 2004-10-29 Wyeth Corp Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP2044941A1 (en) * 1999-08-31 2009-04-08 Bayer Schering Pharma AG Multiple-phase formulation of drospirenone and estradiol as a contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
SG10201701904TA (en) 2017-05-30
EA016625B1 (ru) 2012-06-29
DK1747001T3 (en) 2019-02-04
EA201200377A1 (ru) 2012-08-30
US20050250747A1 (en) 2005-11-10
US20120202779A1 (en) 2012-08-09
WO2005105103A2 (en) 2005-11-10
JP6153967B2 (ja) 2017-06-28
KR20160150113A (ko) 2016-12-28
TWI374735B (en) 2012-10-21
EP1747001A2 (en) 2007-01-31
MXPA06012567A (es) 2006-12-15
EA201200377A8 (ru) 2018-01-31
US8163721B2 (en) 2012-04-24
LT1747001T (lt) 2019-01-25
PA8631801A1 (es) 2006-11-09
JP2007535519A (ja) 2007-12-06
KR20150058555A (ko) 2015-05-28
CA2562296A1 (en) 2005-11-10
JP2017048253A (ja) 2017-03-09
JP6134491B2 (ja) 2017-05-24
BRPI0510493A (pt) 2007-11-13
JP2015187157A (ja) 2015-10-29
JP2013018787A (ja) 2013-01-31
EA031227B1 (ru) 2018-12-28
SV2006002100A (es) 2006-02-15
EP1747001B1 (en) 2018-10-10
AR048722A1 (es) 2006-05-17
AU2005237255B2 (en) 2011-07-07
WO2005105103A3 (en) 2006-09-08
HUE041475T2 (hu) 2019-05-28
NZ586107A (en) 2012-05-25
IL178458A0 (en) 2008-04-13
IL178458A (en) 2016-08-31
ECSP066999A (es) 2006-12-29
KR20070004919A (ko) 2007-01-09
PE20060467A1 (es) 2006-06-11
KR101812160B1 (ko) 2017-12-27
CR8709A (es) 2007-08-28
AU2005237255A1 (en) 2005-11-10
ES2704999T3 (es) 2019-03-21
NO341685B1 (no) 2017-12-18
TW200603781A (en) 2006-02-01
MY151322A (en) 2014-05-15
UY28875A1 (es) 2005-11-30
US20150174142A1 (en) 2015-06-25
SG152288A1 (en) 2009-05-29
CN103127156A (zh) 2013-06-05
NO20065499L (no) 2006-11-29
KR20130022425A (ko) 2013-03-06
EA200601908A1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
IL178458A0 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
DK1827412T3 (da) Sammensætninger til anvendelse i kirurgi
EP1841545A4 (en) ANTI-ADHESION AGENT OF ASPHALT
HUE041365T2 (hu) Demodikózis elleni szer
GB0403780D0 (en) Therapeutic agents
NO20071297L (no) Farmasøytisk sammenseting omfattende drospirenon og etynylestradiol
EP1844792A4 (en) THERAPEUTIC AGENT AGAINST OBSTIPATION
FI20041057A (fi) Pelkistysainekoostumus
GB0421298D0 (en) Cellular bandage
GB0400775D0 (en) Gel composition
GB0400193D0 (en) Therapeutic agents
GB0805741D0 (en) Prophylactic and therapeutic agents and uses therefor
GB0400310D0 (en) Anti-incrustation agent
GB0424497D0 (en) Anti-inflammatory agent
GB0408959D0 (en) Therapeutic agent
HU0500490D0 (en) Intra-uterine contraceptive
HU0500288D0 (en) Intra-uterine contraceptive
GB0400196D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents
GB0403779D0 (en) Therapeutic agents
GB0407993D0 (en) Therapeutic methods and compositions for use therein
GB0418363D0 (en) Therapeutic methods and compositions for use therein
EP1759703A4 (en) IMMUNOSTIMULATING AGENT AND INTERF ROGEN
GB0422917D0 (en) Therapeutic compositions and devices
PL368096A1 (en) Wetting-washing agent